First Quarter 2022 Financial Results
Biodesix today announced that new data were published in the peer-reviewed journal, Diagnostics (Basel), in an article titled, “Analytic and Clinical Validation of a Pan-Cancer NGS Liquid Biopsy Test for the Detection of Copy Number Amplifications, Fusions and Exon Skipping Variants.”
Fourth Quarter and Fiscal Year 2021 Lung Diagnostic Revenue of $5.4 Million and $18.7 Million Increased 48% and 49% over the comparable 2020 periods
Biodesix announced impactful data on the Primary Immune Response (PIR) test at the IASLC 2022 Targeted Therapies of Lung Cancer Meeting.
Biodesix CEO named in The Healthcare Technology Report’s list of Top 25 Biotech CEOs of 2022, recognizing the most accomplished executives in biotech.
Genomic and proteomic diagnostics for lung cancer help physicians better identify patients eligible for targeted therapy or clinical trial enrollment.
Biodesix, Inc., a data-driven diagnostic solutions company with a focus in lung disease, appoints Dr. Jon Faiz Kayyem to the board of directors.
Spesana and Biodesix Inc. announced today that they have partnered to further streamline and automate the use of molecular diagnostics in clinical workflows across the United States utilizing Spesana’s digital platform solutions for comprehensive lung cancer management.
Biodesix, Inc. announced new interim data published from the large multi-center observational registry study INSIGHT utilizing its novel predictive and prognostic blood-based host immune classifier (the VeriStrat test) to stratify ICI treatment response in patients with advanced NSCLC.
Biodesix, Inc. today announced its financial and operating results for the third quarter ended September 30, 2021 and provided a corporate update.